tally toxic in many species and induces cleft palate in the C57BL/6N mouse embryo. Palatogenesis in mouse and human embryos involves homologous processes at the morphological, cellular, and molecular levels. In organ culture, mouse and human palates respond similarly to TCDD. The present study quantitates the expression of AhR, ARNT, and CYP1A1 mRNA in human embryonic palates in organ culture. Palatal tissues were exposed to 1 ؋ 10 ؊10 , 1 ؋ 10 ؊9 , or 1 ؋ 10 ؊8 M TCDD or control medium and sampled at 0, 2, 4, and 6 hours for quantitative RT-PCR using a synthetic RNA internal standard. Similar measurements of CYP1A1 gene expression were collected for mouse palates cultured in this model. In human palates, AhR expression correlated with ARNT and CYP1A1 mRNA expression. TCDD induction of CYP1A1 was time-and concentration-dependent. The expression of these genes presented a uniform and continuous distribution across the group of embryos, with no subset of either high or low expressors/responders. The ratio of AhR to ARNT was approximately 4:1. AhR mRNA increased during the culture period in both treated and control subjects; however, ARNT expression was relatively constant. TCDD did not alter either AhR or ARNT expression in a consistent dose-or time-related manner. Comparison of human and mouse data showed a high correlation across species for the induction of CYP1A1. Human embryos expressed approximately 350 times less AhR mRNA than the mouse, and in earlier studies it was shown that human palates required 200 times more TCDD to produce the same effects. When the morphological, cellular, and molecular responses to TCDD between mouse and human are compared, it seems highly unlikely that human embryos could be exposed to sufficient TCDD to achieve changes in palatal differentiation that would lead to cleft palate.
The environmental contaminant 2,3,7,8-tetrachlorodibenzop-dioxin (TCDD) is developmentally toxic in many species and induces cleft palate in the C57BL/6N mouse embryo (reviewed in Couture et al., 1990; Birnbaum, 1995) . The biological effects of TCDD are mediated through binding to the aryl hydrocarbon receptor (AhR) and the teratogenic effects in mice correlate with expression of a high affinity receptor (reviewed by Schmidt and Bradfield, 1996) . The receptor-mediated pathway includes multiple regulatory peptides, including the heat shock protein HSP-90, and AhR forms a complex with a related basic-HLH protein, the AhR nuclear translocator (ARNT), a member of the PER-ARNT-SIM family of transcriptional regulators (Hoffman et al., 1991; Reyes et al., 1992) . AhR and ARNT mRNA and protein are expressed in the developing embryo and are found in palatal epithelium and mesenchyme Abbott and Probst, 1995; Abbott et al., 1994a,b,c) .
Formation of the secondary palate in the mouse or human requires regulation of complex developmental processes that result in palatal shelf outgrowth from the maxillary arch, expansion across the oral cavity, contact along the palatal medial edge, adhesion, and fusion (reviewed by Zimmerman, 1997) . The etiology of TCDD-induced cleft secondary palate in the mouse involves a failure of the palatal shelves to adhere and fuse (Pratt et al., 1984) . The morphological responses include hyperplasia of the palatal medial epithelial cells that is associated with abnormal proliferation . These effects correlate with altered expression of TGF␣, EGF, EGF receptor, TGF␤1, and TGF␤2, growth factors which regulate proliferation and differentiation of epithelial cells . Similar responses occur in mouse palates exposed to TCDD in a Trowell's-type culture model in which palates are supported on a membrane above the medium. Disruption in epithelial differentiation and proliferation was produced in all of the cultured palates at a concentration of 5 ϫ 10 Ϫ11 M TCDD (EC 100 ) .
Human embryonic palates also respond to TCDD in Trowell's type organ culture and the responses correlate with those described for the mouse palate, including hyperplasia of the medial epithelial cells, altered proliferation and disrupted patterns of growth factor expression (Abbott and Birnbaum, 1991) . The human and mouse craniofacial tissues also respond to TCDD in a suspension culture model (Abbott and Buckalew, 1992) and studies with this model found effects of TCDD on levels of protein and mRNA for EGF, TGF␣, TGF␤1, TGF␤2, TGF␤3, EGF receptor, glucocorticoid receptor, AhR and ARNT (Abbott et al., 1998) . In both culture models, the human palatal responses were concentration dependent, with an EC 100 of 1 ϫ 10 Ϫ8 M. The human embryonic palatal processes are clearly perturbed by TCDD exposure and the morphological, cellular and molecular responses appear very similar to those produced in the mouse. However, the human palates in both the Trowell's and submerged palatal organ culture models responded only at much higher levels of TCDD when compared to the mouse. This divergent sensitivity does not appear to be related to localization of AhR and ARNT in the palate as both mouse and human expression were similar, with both species having similar (although not identical) patterns of expression of the growth factors believed to be critical to regulation of epithelial differentiation and proliferation. Considering the similarities between human and mouse palatogenesis and gene expression, the divergence in responsiveness to TCDD remains unexplained. The present study extends these observations to provide quantitative data for AhR and ARNT mRNA expression and the induction of CYP1A1 in mouse and human palatal tissue. The expression of AhR and ARNT and the induction of CYP1A1 mRNA in human embryonic tissue was correlated with the in vivo and in vitro data from the mouse, and conclusions from these contrasts and comparisons are discussed relative to morphological cellular responses and distribution of TCDD to the palatal tissues in the in vivo and in vitro models.
MATERIALS AND METHODS

TCDD solution preparation.
TCDD of Ͼ99% purity (Radian Corp, Austin, TX) was dissolved in DMSO (Fischer Scientific, Raleigh, NC) to give a 1 ϫ 10 Ϫ4 M stock solution. Aliquots were stored in amber vials at Ϫ80°C. Dilutions were prepared in DMSO to give final concentrations in medium of 0.1% DMSO and 1 ϫ 10 Ϫ10 , 1 ϫ 10 Ϫ9 , and 1 ϫ 10 Ϫ8 M TCDD.
Palatal organ culture. Palatal organ culture for both mouse and human samples was performed as described previously (Abbott et al., 1998; Abbott and Buckalew, 1992) . Dissected mid-facial tissues were placed in 25 cm 2 flasks containing 9 ml of Richter's Improved Modified Eagle's Medium-Ham's F12 Medium (Gibco Laboratories, Grand Island, NY) (1:1), supplemented with 1% fetal bovine serum (Hyclone Laboratories, Logan, UT), 6 mg/ml BSA, 10 g/ml transferrin, 10 ng/ml selenium, 50 g/ml sodium ascorbate, 2.4 mg/ml glucose, 0.6 mg/ml L-glutamine, 50 g/ml streptomycin and 50 units/ml penicillin (Sigma Chemical, St. Louis, MO). Medium contained either 0.1% DMSO or 1 ϫ 10 Ϫ8 , 1 ϫ 10 Ϫ9 , or 1 ϫ 10 Ϫ10 M TCDD. Flasks were gassed with a mixture of 50% O 2 , 45% N 2 , and 5% CO 2 , capped tightly, and incubated at 37°C on a rocker platform. The medium was changed and cultures gassed every 24 h.
Human embryonic craniofacial tissues were shipped overnight in CRCM-30 medium (American Type Culture Collection) at 4°C from the Human Embryology Laboratory, University of Washington, Seattle, WA. Tissues from 23 embryos, ranging in gestational age from 42 to 54 days, a period encompassing development of the secondary palate, were examined. On arrival, the tissues were examined by dissecting microscope, the left and right halves of the craniofacial region separated, and a sample of tissue from each anterior hard palate collected. The remaining sample was placed in culture with the left side of the craniofacial tissue in control medium (0.1% DMSO) and the right side in TCDD-containing medium (the assignment of side to treatment alternated so that left and right were equally represented in control and treated cultures). There were 6 embryos for each TCDD concentration, with collection of sample from each palate at 0 (anterior hard palate), 2 (mid-hard palate), 4 (posterior hard palate), and 6 (soft palate) h. In general (exceptions noted), data were derived from all 6 palatal tissues at each treatment level, with one half cultured in control medium and the other in medium containing 1 ϫ 10 Ϫ10 , 1 ϫ 10 Ϫ9 , or 1 ϫ 10 Ϫ9 M TCDD. Data was obtained from only 5 embryos for the 4-h controls paired with 1 ϫ 10 Ϫ10 M TCDD, the 6-h controls paired with 1 ϫ 10
Ϫ9
M TCDD, and the 0-h tissues for culture in 1 ϫ 10 Ϫ8 M TCDD. Craniofacial tissues from 2 additional embryos were cultured for 48 h with control or 1 ϫ 10 Ϫ8 M TCDD, and samples were collected at 4, 10, 24, and 48 h. Finally, to confirm that gene expression was similar across all palatal regions, craniofacial tissues from 3 embryos were cultured in control medium and anterior, mid-, and posterior hard palate, and soft palate from both left and right sides were collected at 4 h. C57BL/6N embryonic palates were prepared for culture on GD12 by dissection of the midfacial region, including maxillary arch and secondary palatal shelves, as described previously (Abbott and Buckalew, 1992) . The entire mid-facial tissue was placed in culture with 4 embryonic samples per flask and 2 flasks per treatment group and time point. The entire embryonic tissue was collected for preparation of total RNA with 8 embryos collected for each time (0, 2, 4, 6, 10, 24 , and 48 h) and treatment level (1 ϫ 10 Ϫ8 , 1 ϫ 10 Ϫ9 , and 1 ϫ 10 Ϫ10 M TCDD). Quantitative data was obtained from at least 5 of the 8 samples and in some groups from as many as 7 samples. It was not always possible to quantitate mRNA for every sample, particularly for time and treatment groups with very low expression of the mRNAs.
Total RNA preparation. Total RNA was prepared from each tissue sample by extraction with TRI Reagent (Molecular Research Center, Inc., Cincinnati, OH). Mouse palatal total RNA was prepared using standard protocols as described elsewhere (Abbott et al., 1999) . Since the human tissue samples were extremely small, the standard protocol was modified. Tissues were frozen in 50 l of TRI reagent in 1.5 ml tubes, for use with Kontes Pestles (Fisher Scientific, Raleigh, NC). The disposable pestle and cordless motor were used to grind the tissue for at least 10 sec. The homogenate was frozen and thawed again and extracted with 10 l of chloroform. The aqueous phase was combined with isopropanol (1/2 volume) and 0.05 volumes of RNA Tack Resin (Biotecx Laboratories, Inc., Houston, TX) to bind total RNA. The resin-bound RNA was centrifuged to form a pellet that was then washed with 75% ethanol, dried, and the RNA was eluted from the resin with two washes of 10 l each of RNase-free water. Total RNA concentration was determined by OD 260 of a 1:10 dilution in a microcuvette (7 l volume) using the GeneQuant Spectrophotometer (Pharmacia-Biotech, Inc., Piscataway, NJ).
Quantitative RT-PCR. Quantitative RT-PCR was performed using an RNA internal standard (IS), specifically synthesized for each mRNA under study. Primers were selected to be species specific using gene sequences for human AhR, ARNT, and CYP1A1 and mouse CYP1A1. Internal standards were prepared from primers that included a T7 polymerase sequence, the gene primer sequences, and sequences that are homologous to regions of the pUC-19 plasmid (Promega, Madison, WI). The internal standard construct is illustrated in a schematic in Figure 1 . Gene and IS primers were synthesized by Genosys Biotechnologies (The Woodlands, TX). Linearized pUC plasmid provided the template for a PCR reaction with the IS primers, the subsequent cDNA was purified (Wizard™ PCR Preps, Promega, Madison, WI), and T7 polymerase (Ambion T7-MEGAshortscript™, Ambion, Austin, TX) was used to transcribe cRNA for use as an internal standard. The DNA template was removed by DNase digestion prior to purification of the RNA internal standard.
Each IS incorporated the primer sequences of the gene, separated by a pUC sequence whose length is selected to result in a final RT-PCR product of a 30 -50 base difference from the amplified product from the mRNA. For RT-PCR, the total RNA was added at a constant level to each of 5 PCR tubes, but IS RNA was added at increasing levels, creating an IS concentration range that included the expected level of mRNA in the sample. Total RNA and IS were reverse transcribed using the reverse primer for the gene, and PCR was amplified in a 96-well thermocycler for 0.2 ml PCR tubes (MJ Research, Inc, Watertown, MA). Reagents included AMV Reverse Transcriptase (23,000 units/ml, Promega, Madison, WI), Recombinant RNasin Ribonuclease Inhibitor (40 units/l, Promega, Madison, WI), dNTPs 10 mM in water, pH 7.0, 25 mM MgCl 2 , and Taq DNA polymerase (Thermus aquaticus strain YT1, 5 units/l, Promega, Madison, WI). All PCR reactions were optimized for concentration of MgCl 2 , annealing temperature, and cycle number. The RT-PCR products were separated on 2.8% MetaPhor agarose (FMC BioProducts, Rockland, ME) gels. The ethidium bromide-stained bands were imaged with the Hamamatsu Photonics System (Bridgewater, NJ) and quantitated using NIH Image. The ratio of the IS peak to that of the sample RNA was calculated and regressed against IS concentration to give the level of mRNA in the sample. Data were acquired as pg or fg of mRNA per specified amount of total RNA and then converted to molecules of mRNA/100 fg total RNA (based on the molecular weight of the amplified cDNA as calculated from the base sequence). The expression of the data as molecules per unit of total RNA facilitates comparisons between studies, since the number of molecules of mRNA represented by a pg or ng amount of IS will depend on the size of the transcript, which in turn varies with the position of the primers selected.
Primers and PCR conditions. AHR primers were selected based on the GenBank sequence L19872, the complete mRNA codon sequence from cultured human HeLa cells (Dolwick et al., 1993) . These primers produced a 296-nucleotide product with the forward primer spanning bases 1454 -1477, and the reverse at bases 1749 -1726 (forward ϭ 5Ј GGA CTT GGG TCC AGT CTA ATG CAC 3Ј; reverse ϭ 5Ј AGC CAG GAG GGA ACT AGG ATT GAG 3Ј). The AhR IS primers incorporated a 295-base sequence of pUC9 (this is the same as the pUC19 sequence) and produced a 343-base product (forward primer ϭ TAA TAC GAC TCA CTA TAG GGG ACT TGG GTC CAG TCT AAT GCA CCA GAA GTG GTC CTG CAA CTT TAT CC; reverse ϭ TTT TTT TTT TTT TTT TTT AGC CAG GAG GGA ACT AGG ATT GAG CAG TGC TGC CAT ACC CAT). The reactions included 15 ng of total RNA, IS concentrations ranging from 250 to 5 fg and 4 l of 25 mM MgCl 2 to give a final RT reaction volume of 20 l and a total volume for the PCR reaction 50 l. PCR dissociation occurred at 94°C for 15 sec, anneal at 56°C for 1 min, extension at 72°C for 30 s, and was repeated for 35 cycles total.
Primers for ARNT were selected based on the GenBank sequence M69238, a mRNA clone from human liver (Hoffman et al., 1991) . ARNT primers produced a 238-nucleotide product from the coding region: the forward primer spanned bases 2138 -2161 and the reverse, bases 2375-2352 (forward ϭ 5Ј CCC TAG TCT CAC CAA TCG TGG ATC 3Ј; reverse ϭ 5Ј GTA GCT GTT GCT CTG ATC TCC CAG 3Ј). The ARNT IS primers incorporated a 226-base sequence of pUC9 and produced a 275-base product (forward primer ϭ TAA TAC GAC TCA CTA TAG GCC CTA GTC TCA CCA ATC GTG GAT CCA TTG CTA CAG GCA TCG TGG TG; reverse ϭ TTT TTT TTT TTT TTT TTT GTA GCT GTT GCT CTG ATC TCC CAG GCA TCT TAC GGA TGG CAT GAC AG). The reactions included 15 ng of total RNA, IS concentrations ranging from 100 to 1 fg, and 4 l of 25 mM MgCl 2 in the 20 l RT reaction and 4 l MgCl 2 in the PCR reaction to give 50 l final. PCR dissociation was at 94°C for 15 s, anneal at 57°C for 1 min, and extension at 72°C for 30 s; this cycle was repeated for a total of 35 times.
Human CYP1A1 primers were selected from the GenBank Sequence X02612 (Jaiswal et al., 1985) mRNA sequence from human lymphocytes. The primers produced a 148-nucleotide product from exon 7, with the forward primer from bases 7076 -7097 and the reverse at bases 7204 -7224 (forward ϭ TAG ACA CTG ATC TGG CTG CAG; reverse ϭ GGG AAG GCT CCA TCA GCA TC). The IS primers incorporated a 139-base sequence of pUC19 and produced a 180-base product (forward primer ϭ TAA TAC GAC TCA CTA TAG GTA GAC ACT GAT CTG GCT GCA GTA ACT ACG ATA CGG GAG GGC TTA CC; reverse ϭ TTT TTT TTT TTT TTT TTT GGG AAG GCT CCA TCA GCA TCA AAG TTG CAG GAC CAC TTC TGC G). The reactions included 20 ng of total RNA and IS concentrations prepared in several ranges to accommodate the wide range of mRNA in the various samples (10 pg to 0.05 fg). In the RT step, 4 l of 25 mM MgCl 2 was added per 20 l of total reaction volume, and no additional MgCl 2 was added to the PCR buffer. PCR dissociation was at 94°C for 15 s, anneal at 54°C for 1 min, and extension at 72°C for 30 s, with 35 cycles total.
Mouse CYP1A1 primers were selected based on GenBank sequence M10021 Kimura et al., 1984) , and these primers produced a 230 nucleotide product spanning intron C, with the forward primer from bases 1051-1070 and the reverse at bases 1280 -1261 (forward ϭ CCT CTT TGG AGC TGG GTT TG; reverse ϭ TGC TGT GGG GGA TGG TGA AG). The IS primers incorporated a 226-base sequence of pUC19 and produced a 265-base product (forward primer ϭ TAA TAC GAC TCA CTA TAG GCC TCT TTG GAG CTG GGT TTG CAT TGC TAC AGG CAT CGT GGT
FIG. 1.
Schematic of the design of the internal standard (IS) used in the quantitative RT-PCR reactions. The DNA construct included a sequence for T7 RNA polymerase binding, a gene-specific primer recognition sequence (in this case CYP1A1), and pUC plasmid-specific primer sequences. Primers (shown as Foward and Reverse IS Primer) for preparing the DNA internal standard amplified a specific length of pUC plasmid referred to as a spacer. The size of the "spacer" was selected to give a band on the gel that would be a different size relative to the band produced from mRNA. This DNA template was reverse transcribed, using T7 RNA polymerase to produce the RNA IS (in this example, the RNA IS included CYP1A1 gene-specific primer binding sites). The IS RNA and total RNA from a sample would be combined in the RT-PCR tubes and reverse transcribed using the gene specific reverse primer and then amplified with gene specific (in this example, CYP1A1) forward and reverse primers.
G; reverse ϭ TTT TTT TTT TTT TTT TTT TGC TGT GGG GGA TGG TGA AGG CAT CTT ACG GAT GGC ATG ACA G). The reactions included 20 ng of total RNA and IS concentrations ranging from 1000 to 1 pg were prepared in 3 sets to accommodate the wide range of mRNA expression. In the RT step, 4 l of 25 mM MgCl 2 was added per reaction, and no additional MgCl 2 was added to the PCR buffer. The PCR reaction for this primer pair required Stratagene Buffer #2 and Master Mix from the Opti-Prime™ PCR Optimization Kit (Stratagene, Menasha, WI), with dissociation at 94°C for 15 s, anneal at 55°C for 1 min, extension at 72°C for 30 s, up to 35 cycles total.
Statistical analysis. Statistical analyses were performed in SAS (SAS 1989 (SAS , 1990 (SAS , 1992 . Except where otherwise noted, all analyses were performed on log (base 10) transformed gene product concentrations. Mixed-effects linear models (using SAS Proc MIXED) were used to estimate group means and to test for significant effects of treatment and time point. Maximum likelihood estimation was used in these analyses. The model for each of the gene products (AhR, ARNT and CYP1A1) included the fixed-effects DOSE GROUP ϫ TREATMENT ϫ HOUR and PCRDATE nested within DOSE GROUP and the random effect SUBJECT (representing individual embryos). This allowed for a separate intercept for each combination of dose group, treatment, and time point with an adjustment for any effect of PCR run. It also took into account the variation due to subject. Age of the embryo and side of the palate were not significant predictors in any of the three models and were removed from each analysis. Treatment effect was examined by testing the difference between the treated and control groups within each time point and dose group. To look at the effect of time on the gene levels, each treatment by time mean was tested for difference from the appropriate (control or treated within the dose level) zero hour mean. Differences between sequential time points were also examined within each treatment group.
All comparisons were performed in two steps. First, pairwise t-tests were run within the mixed-effects linear model described above. The second step was to run simulations based on the data sets and this was done to verify the results of the tests of treatment and time effects. For each gene, 200 data sets were created by drawing random samples with replacement from the original data set. The simulated data sets retained the structure of the original data set, except that the sides of palates were randomly reassigned to treatment or control groups. The treatment comparisons were rerun in each of the data sets and the probability of each original result examined. Similarly, 200 data sets were simulated, with the hour being reassigned randomly and the original results of the time comparisons compared with the simulated results. The pairwise tests were asymptotically correct; however, we were concerned that with the small sample sizes available we might obtain some spurious results. By calculating the results for 200 simulated data sets, we were able to view the distribution of each result and evaluate the appropriateness of the original p-values. The results of the simulations were very consistent with the results of the original model, increasing confidenence in the results.
For human CYP1A1, many control samples were below the limit of detection. Analyses were performed, substituting a range of values from 0.5 to 2.5 times the lowest detectable value for these samples. As each gave essentially the same outcome, a set value of 0.0002 molecules/100 fg total RNA (just below the lowest detected value) was assigned to these points.
Pearson product-moment correlations between the CYP1A1 and AhR and ARNT data were calculated, both with and without the two samples at later time points. Partial correlations were examined by adjusting for treatment, time, subject, gene (AhR, ARNT) and combinations of those factors.
Two smaller experiments were analyzed separately. In the first, 2 embryos were cultured in control or 10 Ϫ8 M TCDD and collected at 4, 10, 24 and 48 h. In the second, 3 embryos were cultured in control medium for 4 h and then divided by side and region to examine any effects of side or position. The first looked at levels of AhR and ARNT, the second at AhR only. These experiments were analyzed similarly, using a repeated-measures analysis (using SAS Proc Mixed), with embryo as the subject and all measures for an embryo considered as repeated measures. In the first analysis, with the side-by-position values being the measures repeated within each subject, the model AhR ϭ Intercept ϩ b ϫ SIDE ϩ c ϫ POSITION was used, which included side and position as predictors. The means of the side-by-position values were determined and a repeated-measures analysis (SAS Proc Mixed) applied with the model AhR ϭ Intercept ϩ b ϫ side ϩ c ϫ position, and with the side*position values being the measures repeated within each subject. The interaction between side and position was not significant and was removed from the model. The model for the second included TREATMENT ϫ HOUR as a predictor.
The C57BL/6N data set for in vitro expression of CYP1A1 was analyzed using a mixed effects linear model. The model included, as predictors, the fixed-effect DOSE GROUP ϫ HOUR and the random-effects PCRDATE and EMBRYO. Differences between treatment by time-point means were then tested with pairwise t-tests.
Mouse and human in vitro values and mouse in vivo and in vitro values were compared, using the treatment by time-point means estimated by the model in each experiment. Regression lines and Pearson correlation coefficients were calculated using the means from the comparable treatment by time groups. In the comparison of the mouse in vivo and in vitro CYP1A1 values, the three in vitro control means for each time point were first averaged, in order to compare them to the in vivo control groups. The average ratio of human to mouse in vitro and mouse in vivo to in vitro values was calculated as the mean of the ratios of the treatment by time-point means. The average ratio of AhR/ARNT was calculated for mice as the average of the AhR/ARNT values for each embryo. Similarly, for humans, this average was calculated as the average of the ratios for each sample. All ratios were calculated on the original data scale (molecules/100 fg). Where model means were used, they were first backtransformed from the log scale.
RESULTS
In the experimental design, different treatments were applied to left and right halves of each embryonic sample, and subsamples of each side were taken in the anterior to posterior direction at 4 time points. This design requires that side and region express the genes similarly, allowing any significant differences to be attributed to treatment or changes in gene regulation linked to advancing developmental stage (timerelated effects). This assumption was tested by quantitating the expression of AhR across different sides of the craniofacial sample (left versus right) and regions (anterior to posterior, 4 positions) for 3 embryonic tissues cultured in control medium for 4 h. The means (expressed as molecules per 100 fg total RNA) and 95% confidence intervals from this model were as follows: left ϭ 0.68 (0.34, 1.36), right ϭ 0.54 (0.26, 1.12), anterior palate ϭ 1.01 (0.38, 2.69), mid-hard palate ϭ 0.35 (0.13, 0.94), posterior hard palate ϭ 0.93 (0.35, 2.48), and soft palate ϭ 0.41 (0.14, 1.20). There was no interaction between side and position and no significant differences between left and right (p ϭ 0.642) or among positions (p ϭ 0.300).
The expression of AhR and ARNT mRNA was determined by quantitative RT-PCR and representative images of the electrophoretic gels of cDNA amplified from mRNA and internal standard are presented for AhR and ARNT in Figure 2 (A and B, respectively). The means with 95% confidence intervals are shown in Table 1 , with the outcomes of the statistical analyses in Table 2 . The expression of AhR at 2, 4 and 6 h in culture increased significantly (p Ͻ 0.05 original data sets, p Ͻ 0.1 in the simulations) for many of the treated and control tissues when compared to the initial expression at 0 h. The elevation of AhR did not have concentration or time-dependent trends and similar increases were not observed for ARNT mRNA. The only significant change in ARNT expression was a decrease in the 4-h control of the high dose set (p ϭ 0.043, p ϭ 0.030 simulations).
The response to TCDD was evaluated by comparison of the paired control and treated samples at each sampling time and a significant decrease (p ϭ 0.018, simulations p ϭ 0.05) was observed at 2 h for the tissues exposed to 1 ϫ 10 Ϫ9 M TCDD. When expression at each time is adjusted for the 0 h expression level, significant increases are detected at 2 and 6 h for the group exposed to 1 ϫ 10 Ϫ8 M TCDD (p ϭ 0.005, simulation p ϭ 0.085 and p ϭ 0.022, simulation p ϭ 0.07, respectively).
TCDD exposure did not significantly alter expression of ARNT at any of the sampling times. Table 3 presents the expression of AhR and ARNT after 4, 10, 24, and 48 h in culture. This data was obtained from 2 embryonic samples cultured with 1 ϫ 10 Ϫ8 M TCDD or control medium, and no significant differences in AhR expression were detected across time or with treatment. Expression of ARNT in the control increased significantly at 24 h (p Ͻ 0.05), but decreased at 48 h (p Ͻ 0.05), when compared to the 4 h level. In the treated group, ARNT mRNA increased significantly at 10, 24, and 48 h compared to the 4 h value for that treatment (p Ͻ 0.01, p Ͻ 0.01, and p Ͻ 0.05, a 95% confidence intervals are shown in parentheses. Number of embryonic samples ϭ 6, except for 4-h control of the 1 ϫ 10 Ϫ10 M TCDD, 6-h control of the 1 ϫ 10 Ϫ9 M TCDD, 0 h for 1 ϫ 10 Ϫ8 M TCDD, and 4-h 1 ϫ 10 Ϫ9 M TCDD, which all had n ϭ 5. Hour ϭ time after start of culture.
respectively). TCDD exposure significantly increased ARNT mRNA at 48 hours when compared to the 48 hour control level (p Ͻ 0.01).
There is a partial correlation between AhR and ARNT that is very high (rho ϭ 0.72, p Ͻ 0.001) after adjusting for any association due to concentration group, treatment or time. The expression of AhR was 3.9 times greater than that of ARNT. This value is based on calculation of the ratio of AhR to ARNT for each embryo by averaging across time and treatment and then calculating the average across all embryos.
The expression of CYP1A1 was examined in the same tissue samples from which AhR and ARNT mRNA expression was determined. An example of the electrophoretic gel of cDNA amplified from CYP1A1 mRNA and internal standard is shown in Figure 2C . Table 4 presents the CYP1A1 back-transformed estimates of the means and 95% confidence intervals and Table  5 shows the outcome of statistical analysis of the data. (Note that in contrast to the evaluation of AhR and ARNT, this analysis included the 2 samples from 4, 10, 24, and 48 h with the 0 -6-hour data set.) CYP1A1 mRNA was expressed only at very low levels in the uninduced control tissues (mean ϭ 0.002 molecules per 100 fg total RNA) and the limit of detection for this gene in the quantitative RT-PCR assay was considered to be 0.0002 molecules/100 fg total RNA. In general, the induction of CYP1A1 in the human embryonic palatal tissue was time-and concentration-dependent. Significantly increased mRNA was detected at 2 h in the tissues exposed to 1 ϫ 10 Ϫ8 M TCDD (0 h vs. 2 h, p Ͻ 0.001), at 4 h after exposure to 1 ϫ 10 Ϫ9 M TCDD (control vs. treated, p Ͻ 0.01), and at 6 h after the 1 ϫ 10 Ϫ10 M TCDD (control vs. treated, p Ͻ 0.001) ( Table  5) . Induction was also significant at 10 and 24 h (p Ͻ 0.001 and p ϭ 0.011, respectively). The 6 h control value was elevated relative to 0 h expression for all control groups, but did not differ significantly from the 4 h control expression in any of the control sets. The apparent increase in CYP1A1 during culture in control medium may reflect a response to culture conditions, but was generally minimal when compared to the induced expression in any of the treated groups (control versus treated p Ͻ 0.001). The apparent increase in the controls at 24 and 48 h and the low value for TCDD-exposed tissue at 48 h may be related to the low sample size for those times.
It was of interest to evaluate the uniformity of expression of these genes across the individual embryonic palates (18 embryos were compared for AhR and ARNT and 20 for CYP1A1). In evaluating the potential for "high" or "low" expressors of AhR or ARNT, a comparison of the ratios of treated to control values for each embryo (Fig. 3 A and B) suggested that the response to treatment was fairly consistent across embryos. In addition, random effects estimates were calculated that represent the proportionate change in the level of AhR, ARNT and CYP1A1 due to individual embryonic subject, after adjusting for the effects of treatment, time, dose group and PCR run (Fig. 4 A, B , and C, respectively). Based on these analyses, there is not a subset of individuals that can be considered high or low responders to treatment or expressors of the AhR, ARNT, or CYP1A1 genes.
Statistical analysis of the relationship among expressions of CYP1A1, ARNT and AhR in the individual embryonic samples indicated that expression of mRNA for AhR and ARNT was correlated with CYP1A1 (p ϭ 0.002, p ϭ 0.014, respectively). AhR and CYP1A1 remain correlated after adjustments are made for treatment, time, and ARNT (p ϭ 0.045). How- Number of embryonic samples ϭ 6 for 0, 2, 4, and 6 h, except for 0-h 1 ϫ 10 Ϫ8 M TCDD, where n ϭ 5, and at 10, 24, and 48 h where n ϭ 2. Hour ϭ time after start of culture. ND ϭ no data available for these times. ever, after partialling out AhR, the association of ARNT with CYP1A1 no longer remains significant (p ϭ 0.73). This suggests that the correlation of ARNT with CYP1A1 is probably due to the association between AhR with ARNT. The data support a strong functional relationship between AhR expression in the human embryonic palatal tissue and the induction of CYP1A1. For comparison with the human tissues, C57BL/6N mouse embryonic palates were exposed to 1 ϫ 10 Ϫ10 , 1 ϫ 10 Ϫ9 , or 1 ϫ 10 Ϫ8 M TCDD or control medium in organ culture. CYP1A1 mRNA was quantitated in palates collected at 2, 4, 6, 10, 24, and 48 h, and the data is presented in Table 6 with the statistical analyses in Table 7 . A representative gel of the amplified mRNA and internal standard are shown in Figure  2D . In palates cultured with control medium, CYP1A1 was expressed at low levels and the only significant increase occurred at 24 h (p ϭ 0.002 compared to the 2-h value; and p Ͻ 0.001 versus the 10-hour value). TCDD exposure resulted in time-and concentration-related induction of the gene. Exposure to 1 ϫ 10 Ϫ10 M TCDD produced a significant increase in CYP1A1 mRNA at 6 h relative to the 2-or 6-h control or the 4-h treated level. Gene expression in that treated group was also significantly induced at 10, 24, and 48 h compared to either the control for each time point or the 2-h control. The induction appeared to plateau after 6 h, as comparison with the preceeding time point was not significant after 10 h. Exposure to 1 ϫ 10 Ϫ9 or 1 ϫ 10 Ϫ8 M TCDD resulted in a similar profile of responses, except that significant induction was first detectable at 2 h for both concentrations. For tissues treated with 1 ϫ 10 Ϫ9 M TCDD, even though the expression was significantly increased relative to the controls, the degree of induction between succeeding time points was gradual and no significance was detected when comparing each value after 4 h with the preceding time point. For the group exposed to 1 ϫ 10 Ϫ8 M TCDD, a low mean at 4 h and a high mean at 24 h resulted in significant differences between consecutive time points (4 vs. 6, 10 vs. 24, and 24 vs. 48). The 4-h value for the 1 ϫ 10 Ϫ8 M TCDD-treated group was also not significantly different from the 2-or 4-h controls or the 2-h treated value. However, induction in the 1 ϫ 10 Ϫ8 M TCDD-treated group is significant when comparing treated means at 2, 6, 10, 24, and 48 h to either time-matched controls or the 2-h control.
TABLE 5 Human CYP1A1 Statistical Tests of Time and Treatment-related Effects
The induction of CYP1A1 in human palatal tissue was compared to that of C57BL/6N mouse palates in culture and a high degree of correlation was observed (p Ͻ 0.001, r 2 ϭ 0.662, correlation coefficient ϭ 0.814). This is illustrated in Figure 5A , which is a plot of human and mouse mRNA expression in molecules per 100 fg of total RNA (both axes are log scale), and each symbol on the plot represents either a control (solid) or treated (open symbol) value at the specified time point. The human CYP1A1 levels were considerably lower than those of the mouse, as illustrated in the differences in the X and Y axes scales as well as in a mean ratio of human to mouse expression of 0.0023 (calculated as group means   FIG. 3 . The effects of TCDD exposure on expression of AhR (A) and ARNT (B) was compared across individuals. All of the TCDD exposure levels are represented (of the 18 embryos shown, 6 were in each treatment set) and symbols for each time point show the ratio of TCDD/control expression. Although some variation between individuals is present, responses to treatment (regardless of exposure level) were fairly consistent across embryos. 0 F, 2 E, 4 ‚, 6 ᮀ hours after start of culture. The 0-h ratio represents uncultured values from left vs. right sides of the craniofacial sample. On the X axis, embryos are identified by a number reflecting the order in which the tissue was received and placed into testing. The identification number for each embryo remains the same across Figures  3A, B and 4A , B, C. across treatment and time, range of ratio values ϭ 4 ϫ 10 Ϫ6 to 0.02).
The expression and induction of CYP1A1 in cultured mouse palates as determined in this study was compared to expression in embryonic tissues that were exposed in utero ( Figure 5B ; data from a related report, Abbott et al., 1999) . In the in vivo study, pregnant mice were dosed orally on GD12 with 24 g TCDD/kg body weight and embryonic palates were collected at 2, 4, 6, 24, and 48 h and examined by RT-PCR to quantitate CYP1A1 mRNA. The correlation between the in vivo and in vitro values across time was statistically significant (correlation coefficient ϭ 0.745, r 2 ϭ 0.554, p ϭ 0.014) and the relative ratio between in vivo and in vitro was 2.81 (range of ratio values ϭ 0.1 to 14.2). The cultured tissues responded to TCDD with induction of the CYP1A1 mRNA in a manner indistinguishable from that of in vivo exposed embryos.
DISCUSSION
Human embryonic craniofacial tissues express AhR, ARNT, and CYP1A1 mRNA during palatogenesis and respond to Number of embryos ϭ 6, except for 2-h Control and 4-h TCDD 1 ϫ 10 Ϫ10 M, which had 5 embryos each and 6-h 1 ϫ 10 Ϫ10 M, 1 ϫ 10 Ϫ9 M, and 1 ϫ 10
Ϫ8
M TCDD groups, which had 7 embryos; 0-h value [40.7 (10.1, 163.7)] was based on 2 embryos and was not included in contrasts by treatment and time.
Hour ϭ time after start of culture.
FIG. 4.
The potential for individuals to be either unusually high or low expressors of AhR or ARNT, or to have different sensitivity to TCDD exposure was evaluated through calculation of random effects estimates. These estimates, on the log scale, represent individual subject's deviations from the overall mean, proportionate to the changes in the levels of AhR, or ARNT, or CYP1A1 after adjusting for effects of treatment, time, and dose group. The plots are back-transformed data that are a dimensionless ratio. The range of expression of each gene is continuous, without subsets of high or low expressors/responders among this group of subjects. Individual embryos are identified as described in Figure 3. TCDD exposure in culture with a time-and concentrationrelated induction of CYP1A1. The developmental expression of these genes and the response to TCDD presented a uniform and continuous distribution across the group of embryos, and there was no subset of individuals with either unusually high or low expression or response to treatment. AhR was expressed at approximately 4 times the level of ARNT with expression of these genes highly correlated within individuals (adjusting for associations due to concentration, treatment group or time). Higher levels of AhR relative to ARNT protein were also reported for female Sprague-Dawley rats as well as in several mammalian cell culture lines derived from both hepatic and non-hepatic sources for protein (Pollenz et al., 1998; Holmes and Pollenz, 1997) . The ratio of AhR:ARNT in these studies ranged from 0.3 in H411E cells up to 10 in Hepa-1 cells, and the present report of a ratio of 4 for human embryonic cells is approximately central to that range.
A strong correlation was also detected between CYP1A1 and AhR, suggesting that individuals with higher levels of AhR may also be more likely to respond with higher induction of CYP1A1, an outcome that might be expected, based on the functional relationship between AhR expression and the induction of CYP1A1. The expression of ARNT was not correlated with expression of CYP1A1, once the adjustment for the association of AhR with ARNT was made. There is a substantial literature establishing the transcriptional regulation and induction of CYP1A1 by TCDD through AhR-mediated pathways (reviewed by Whitlock et al., 1996) . A number of studies demonstrated that the expression and activity of the various isoforms of the P450 enzymes varied with developmental stage, and in the human embryo CYP1A1 mRNA was detected by RT-PCR in liver, lung, kidney and adrenal samples aged 45-145, days with detection in liver as early as GD45 (Omiecinski et al., 1990) , and enzymatic activity could also be detected in the hepatic tissue at this developmental stage (reviewed in Juchau et al., 1992; Yang et al., 1995; Miller et al., 1996) . Hayashi et al. (1994) also reported correlation between human expression of AhR and ARNT mRNA and association with induction of CYP1A1 in peripheral blood samples from 20 individuals. In that report, quantitation was based on radioactivity in PCR amplicons and units of expression were relative values based on comparing different loading of total RNA into the reactions. However, Vanden Heuvel et al. (1993) examined CYP1A1 induction by TCDD in human peripheral blood lymphocytes using a quantitative RT-PCR method (the method used in our study was based on their protocols). In the mitogenstimulated lymphocytes, the mean expression of CYP1A1 was 24,600 molecules/100 ng total RNA (comparable units to compare with Table 4 ϭ 0.0246 molecules/100 fg) and this value is similar to levels found in the uncultured embryonic facial tissues. A 10 nM TCDD exposure induced CYP1A1 mRNA approximately 20-fold in lymphocytes cultured for 3 days, and after 6-h exposure of the craniofacial tissues to 10 nM TCDD, CYP1A1 mRNA was also induced approximately 22-fold.
In our earlier studies the expression of AhR and ARNT in human palates was determined by in situ hybridization (ISH) of mRNA and localization of protein by immunohistochemistry (IMH) for both uncultured palates and palates exposed to 1 ϫ 10 Ϫ10 M or 1 ϫ 10 Ϫ8 M TCDD (Abbott et al., 1998) . In uncultured palates, AhR protein decreased with advancing palatogenesis; however, ARNT expression remained relatively constant. Exposure to 1 ϫ 10 Ϫ10 M TCDD did not produce a major shift in expression of either AhR or ARNT protein.
However, a concentration of 1 ϫ 10 Ϫ8 M TCDD increased protein expression for both AhR and ARNT in the majority of cultured palates. The present quantitative data indicated an increase in AhR mRNA in the relatively short culture period (6 h for most specimens), for both treated and control tissues. These cultures also showed no increase in ARNT mRNA from 0 -6 hours, but the 2 specimens cultured for up to 48 h did have increased expression at the later time points. Also, in contrast to a decrease indicated by ISH for some of the palates exposed to 1 ϫ 10 Ϫ8 M TCDD, AhR mRNA increased in the present study at 2-and 6-h, but only after adjusting for the expression at 0 h. Some of the differences between the ISH and RT-PCR studies may be related to the inability to evaluate the responses across time or before incubation with TCDD in the ISH studies.
Since one of the major goals of this research was to be able to compare human and mouse expression of these genes and their responses to TCDD, the induction of CYP1A1 mRNA was quantitated in mouse and human palatal tissues during culture in identical organ culture systems. In addition, mouse palatal expression of CYP1A1 in culture was compared to in vivo expression in embryonic palatal tissues following exposure to either corn oil vehicle or a teratogenic dose of TCDD (24 g TCDD/kg on GD12) (Abbott et al., 1999) . In vivo exposure of mouse embryonic palates significantly induced CYP1A1 mRNA at 2 h, which was the earliest time point examined. Mouse palates exposed in culture also showed significant time and concentration-dependent induction of CYP1A1, with the higher concentrations producing significant increases in the 2-h samples. Comparison of the responses of palates exposed in vivo and in vitro demonstrated a high degree of correlation across time (Fig. 5B) . A similar comparison between the mouse and human responses in palatal organ culture, across both time and TCDD concentration, showed a high correlation between species for induction of CYP1A1 (Fig. 5A) . These contrasts and correlations (mouse in vivo vs. mouse in culture and mouse in culture vs. human in culture) provide a basis for interspecies comparisons of gene expression and response to TCDD.
The expression of AhR and ARNT for human and mouse palates is shown in Table 8 as range, median and mean expression in molecules per 100 fg of total RNA (mouse data derived from Abbott et al., 1999) . It is apparent that the human expression of both AhR and ARNT is considerably lower than that of the mouse with differences as much as 346-fold (comparing median for AhR) and 135-fold (median for ARNT). The divergence is greater for expression of AhR, and this is also reflected in the ratios of AhR to ARNT expression for each species (mouse ϭ 6.8:1, human ϭ 3.9:1, AhR:ARNT). The differences in expression of AhR and ARNT are also correlated with a considerable interspecies difference in the induction of CYP1A1 mRNA. Although the comparison of mouse and human responses to TCDD was highly correlated as previously discussed, the levels of CYP1A1 mRNA in the mouse were substantially higher than in the human (435-fold greater, a relative difference similar to that observed for AhR expression). This interspecies difference is further illustrated (Table  8) in comparison of the responses to 1 ϫ 10 Ϫ9 M TCDD in culture and between the in vivo and in vitro levels of mouse. The level of induction after 6 h is virtually identical for mouse palates exposed either in vivo or in culture, however the level of expression in human palate after 6 h is 1,547 times lower after the same duration in the identical concentration of TCDD.
The difference in responsiveness may be a function of lower levels of AhR in the human tissue as well as decreased affinity for binding TCDD reported for human AhR. AhR is found in several allelic forms in mice, and the high affinity b allele The expression and induction of CYP1A1 in cultured mouse palates (1 ϫ 10 Ϫ8 M TCDD) was highly correlated with responses in palates of embryos exposed in utero (pregnant mice dosed orally on GD12 with 24 g TCDD/kg body weight). The correlation between the in vivo and in vitro values across time was statistically significant (correlation coefficient ϭ 0.745, r 2 ϭ 0.554, p ϭ 0.014) and the relative ratio between in vivo and in vitro was 2.81 (range of ratio values ϭ 0.1 to 14.2). Control 0 F, 2 }, 4 OE, 6 ଙ, 10 s, 24 ‹, 48 h; TCDD 0 E, 2 {, 4 ‚, 6 ଁ, 10 ᮀ, 24 , 48 ƒ h. In (A), 1 control and 3 TCDD-treated values are shown for each time, although treated values are not identified by specific TCDD concentration. These data are also in Tables 4 and 6 . For human controls, one value was calculated for each time point by averaging controls across the paired treatment sets. (B) Mouse in vivo data reported in Abbott et al., 1998. expressed in the C57BL strain correlates with sensitivity for induction of cleft palate (Poland and Glover, 1980) . In human cells, the AhR is also reported to exist in more than one form, as in HeLa cells AhR is reported to exist in 2 distinct forms (Perdew and Hollenbeck, 1995) . In 6 human cancer cell lines, a range of expression and molecular properties was found; however, the levels of AhR did not predict responsiveness for AHH induction (Wang et al., 1995) . The human and C57BL mouse AhRs differ by almost 10-fold in their affinity for binding of TCDD, with reported Kd values for C57BL of 0.27 nM, human 1.58 nM and the less responsive DBA mice with the b allele, 1.66 nM (Ema et al., 1994) . Manchester et al. (1987) also reported a low apparent affinity for human placental AhR (Kd between 5-8 nM) compared to rat or mouse (1-3 nM).
The differences between mouse and human sensitivity to TCDD are also apparent in comparisons (Table 8 ) of the amount of TCDD required to produce cellular and morphological responses. The exposure regimen used to produce cleft palate in 100% of the fetuses was an oral dose of 24 g TCDD/kg to pregnant female mice on GD12 Birnbaum, 1989, 1990) . Distribution studies showed that the TCDD reached the embryos and palatal tissues rapidly (within 30 min, radiolabeled TCDD was detected) (Abbott et al., 1996) . At 24 h after dosing, 440 pg TCDD was localized per gm palatal wet weight (also expressed as 7800 pg TCDD per gram total protein). After exposure in utero, the embryonic palatal shelves exhibit altered proliferation and differentiation of the medial epithelial cells on GD14, and these changes are related to a failure of opposing palates to fuse. Similar changes in palatal development are observed after exposure of the mouse palates to 5 ϫ 10 Ϫ11 M TCDD in organ culture, and this exposure is sufficient to produce responses in 100% of the exposed cultures (EC 100 , as noted in Table 8 ). For comparison of tissue burdens after in vivo and in vitro exposure, palates exposed to 5 ϫ 10 Ϫ11 M TCDD in medium for 24 h retain 29,000 pg TCDD per gm total protein (Abbott et al., 1996) . This is approximately 3.7 times as much as detected following the in vivo exposure at 24 h. Human embryonic palates of similar developmental stages as the mouse require 200 times more TCDD to alter differentiation and proliferation and effect changes in growth-factor expression ( Table 8) . The difference is apparent in both the concentration in medium that is required to produce effects (1 ϫ 10 Ϫ8 M TCDD) and in the tissue burdens (5.3 ϫ 10 6 pg TCDD per gm total protein) after 24 h exposure. Human palates exposed to 1 ϫ 10 Ϫ8 M TCDD in organ culture exhibit oral and medial epithelial hyperplasia, accompanied by increased proliferation and expression of EGF receptor (Abbott and Birnbaum, 1991) . In addition, TCDD at 1 ϫ 10 Ϫ8 M altered protein levels of AhR, ARNT, glucocorticoid receptor, TGF␣, EGF, EGF receptor, TGF␤1, TGF␤2, and TGF␤3; however, at 1 ϫ 10 Ϫ9 or 1 ϫ 10 Ϫ10 M TCDD, these responses either did not occur or the incidence and severity was much reduced (Abbott et al., 1998) . Limited data is available regarding the tissue levels in human embryos; however, from a sample of 10 embryos aged 8 to 14 weeks, Schecter et al. (1996) measured approximately 1.4 ppt TCDD (lipid adjusted, assuming 0.65% lipid) and a TEQ value of 5.3 ng/kg lipid. This average tissue burden for human embryos is considerably below that required to produce morphological, cellular, or molecular responses in culture palates. As shown in Table 8 , the EC 100 of 3 ϫ 10 5 ppt in cultured palates is approximately 2000 times higher than the average embryonic tissue burden determined in Dr. Schecter's analyses.
In summary, the present study found that relative to the C57BL/6N embryonic mouse, the human embryonic palatal tissue expressed lower levels of AhR and ARNT, the relative expression of AhR to ARNT differed between mouse and human, and the expression and induction of CYP1A1 were lower in human palatal tissue. A situation emerges for the human embryo in which approximately 350 times fewer receptors are expressed; approximately 200 times more TCDD is required to produce the critical effects, and response of a transcriptionally regulated gene (CYP1A1) is approximately 1500 times lower than mouse palates under identical exposure conditions. Based on the only available measured values, the levels of TCDD in human fetuses are approximately 2000 times lower than the effective concentrations for cultured tissues. When all of these factors are considered, it seems highly unlikely that human embryos could be exposed to sufficient TCDD, even under situations of high accidental exposure of the pregnant woman, to achieve changes in palatal differentiation sufficient to produce cleft palate. This does not eliminate the possibility that TCDD could affect other developing systems, or have effects on human embryonic and fetal processes at lower exposures or tissue burdens. However, teratogenic responses such as those induced in C57BL/6N mice are regarded as unlikely to occur in the human.
